Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depigoid Bäume Mix
- Development stage
- Unknown
- Lead developer
- Leti
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Depigoid Bäume Mix is a subcutaneous allergen immunotherapy (SCIT) product developed by LETI Pharma for the treatment of IgE-mediated allergic diseases triggered by tree pollen, such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma. The active ingredient consists of a depigmented, glutaraldehyde-polymerized allergen extract derived from tree pollen, which is adsorbed onto aluminum hydroxide hydrate as an adjuvant. The Depigoid platform utilizes a chemical modification process (depigmentation and polymerization) to reduce the allergenicity of the extract (decreasing IgE binding) while maintaining its immunogenicity. This modification allows for a more rapid up-dosing schedule compared to conventional allergen extracts. The product is available in Germany and has been evaluated in Phase 3 clinical trials assessing its efficacy and safety over multiple pollen seasons.
- Brand names
- Depigoid Bäume Mix
- Other names
- Depigoid Tree MixDepigoid tree pollen extract
02
Targets
TCR (T cell antigen receptor complex)BCR/Ab (Allergen-specific B-cell receptor and antibody)
Beyond the preview
Go deeper on Depigoid Bäume Mix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Depigoid Bäume Mix.